Lupus & antiphospholipid syndrome
Cognitive impairment in a Colombian cohort of patients with systemic lupus erythematosus: A cross-sectional study
Authors' conclusion
In this study, it was found in 16% of patients evaluated with the complete neuropsychological test battery and in 37% with the MoCA screening test.
Study context
- Population
- Colombian patients with SLE attending a third-level hospital
- Outcome
- Cognitive deficit (MoCA screening; confirmation with ACR-recommended neuropsychological test battery)
Methodological detailsdescriptive, third-level hospital
- Descriptive
- Third-level hospital
Main finding
As reported in the abstract
Cognitive deficit
- Abnormal MoCA (<26 points)
- 35 (37.1%)
- Normal MoCA (≥26 points)
- 59 (62.9%)
- Some degree of cognitive deficit (neuropsychological battery, applied to 31 with abnormal MoCA)
- 19 (20%)
- Cognitive impairment
- 15 (15.95% of the total sample)
- Cognitive decline
- 4 (4.25%)
Observational data: associations, not effects.
Further findings
Factors associated with cognitive deterioration (logistic regression, patients undergoing specific tests)
- Lower quality of life, aOR
- 1.05 (CI 1.01-0.09) (CI as printed)
- No association with SLEDAI, prednisolone use, cyclophosphamide use, and depression
Depression (Beck Depression Inventory), some degree
- Patients with some degree of depression
- 41 (48.8%)
Loss of quality of life (LupusCol), median
- Median loss of quality of life
- 21.03% (IQR 10.2 - 40.3)
Original publication
Cognitive impairment in a Colombian cohort of patients with systemic lupus erythematosus: A cross-sectional study. Lupus. Published 15 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →